SCDAA Statement: CMS Cell and Gene Therapy Access Model

Nearly one year ago, the Food and Drug Administration (FDA) approved two new gene therapies for the treatment of sickle cell disease. The Sickle Cell Disease Association of America Inc. [...]

December 5, 2024

OCTOBER LEGISLATIVE BRIEFING

October 1, 2024

JUNE LEGISLATIVE BRIEFING

June 1, 2024

MARCH LEGISLATIVE BRIEFING

March 1, 2024

CMMI Announces the Cell and Gene Therapy Access Model

Today, the Centers for Medicare and Medicaid Innovation (CMMI) announced the launch of their new Cell and Gene Therapy Access Model, a demonstration aimed at improving access to cell and [...]

January 30, 2024

Midterm Election Outcomes and What they Mean for SCD

An update from John Otsuki, SCDAA government relations manager As I am sure you’re aware, the United States recently completed a midterm election. All members of the House of Representatives [...]

December 19, 2023

Sickle Cell Disease is Not a Joke

This weekend’s Saturday Night Live skit about the recent historic approvals of potentially curative gene therapies for sickle cell disease is distasteful at best and harmful at worst. Earlier this [...]

December 18, 2023

June 19, 2023, is Officially Sickle Cell Awareness Day..

Maryland Governor Wes Moore has signed a proclamation to make June 19, 2023, Sickle Cell Awareness Day! This recognition goes a…

December 14, 2023

Afimmune joins the
SCD C.A.R.E.S. Consortium

Dublin, Ireland, 19 June 2023: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced it has

December 14, 2023

Gene Therapy: What You Need to Know (Warrior FAQs)

Two gene therapies were recently approved by the Food and Drug Administration (FDA) to treat sickle cell disease: Casegevy from CRISPR/Vertex and Lyfgenia from bluebird bio. You probably have questions [...]

December 8, 2023

(800) 421-8453

info@sicklecelldisease.org

SCDAA Member

Clinical Trial Finder

News